{"id":"NCT00595790","sponsor":"Valneva Austria GmbH","briefTitle":"Rapid Immunization Study of the Japanese Encephalitis Vaccine IC51","officialTitle":"Phase 3 Study to Compare a Rapid Immunization Regime With the Standard Regime of IC51 as Vaccine for Japanese Encephalitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-09","primaryCompletion":"2006-02","completion":"2007-11","firstPosted":"2008-01-16","resultsPosted":"2014-03-26","lastUpdate":"2014-04-29"},"enrollment":374,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"SINGLE","primaryPurpose":"PREVENTION"},"conditions":["Japanese Encephalitis"],"interventions":[{"type":"BIOLOGICAL","name":"IC51","otherNames":["Japanese Encephalitis purified inactivated vaccine"]}],"arms":[{"label":"IC51 2 x 6 mcg","type":"ACTIVE_COMPARATOR"},{"label":"IC51 1 x 12 mcg","type":"ACTIVE_COMPARATOR"},{"label":"IC51 1 x 6 mcg","type":"ACTIVE_COMPARATOR"}],"summary":"The study investigates a rapid immunization regime of the Japanese Encephalitis vaccine IC51 (JE-PIV) in healthy subjects aged \\> or = 18 years","primaryOutcome":{"measure":"SCR (Seroconversion Rate) at Day 56","timeFrame":"day 56","effectByArm":[{"arm":"IC51 1 x 12 mcg","deltaMin":41.2,"sd":null},{"arm":"IC51 2x6 mcg","deltaMin":97.3,"sd":null},{"arm":"IC51 1x6 mcg","deltaMin":25.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":">0.99"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":2,"exclusionCount":9},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":125},"commonTop":["Myalgia","Headache","Influenza like illness","Fatique","Pharyngolaryngeal pain"]}}